Cargando…

Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological Designs

Background: Routinely collected healthcare data such as administrative claims and electronic health records (EHR) can complement clinical trials and spontaneous reports to detect previously unknown risks of vaccines, but uncertainty remains about the behavior of alternative epidemiologic designs to...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuemie, Martijn J., Arshad, Faaizah, Pratt, Nicole, Nyberg, Fredrik, Alshammari, Thamir M, Hripcsak, George, Ryan, Patrick, Prieto-Alhambra, Daniel, Lai, Lana Y. H., Li, Xintong, Fortin, Stephen, Minty, Evan, Suchard, Marc A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299244/
https://www.ncbi.nlm.nih.gov/pubmed/35873596
http://dx.doi.org/10.3389/fphar.2022.893484
_version_ 1784750922037985280
author Schuemie, Martijn J.
Arshad, Faaizah
Pratt, Nicole
Nyberg, Fredrik
Alshammari, Thamir M
Hripcsak, George
Ryan, Patrick
Prieto-Alhambra, Daniel
Lai, Lana Y. H.
Li, Xintong
Fortin, Stephen
Minty, Evan
Suchard, Marc A.
author_facet Schuemie, Martijn J.
Arshad, Faaizah
Pratt, Nicole
Nyberg, Fredrik
Alshammari, Thamir M
Hripcsak, George
Ryan, Patrick
Prieto-Alhambra, Daniel
Lai, Lana Y. H.
Li, Xintong
Fortin, Stephen
Minty, Evan
Suchard, Marc A.
author_sort Schuemie, Martijn J.
collection PubMed
description Background: Routinely collected healthcare data such as administrative claims and electronic health records (EHR) can complement clinical trials and spontaneous reports to detect previously unknown risks of vaccines, but uncertainty remains about the behavior of alternative epidemiologic designs to detect and declare a true risk early. Methods: Using three claims and one EHR database, we evaluate several variants of the case-control, comparative cohort, historical comparator, and self-controlled designs against historical vaccinations using real negative control outcomes (outcomes with no evidence to suggest that they could be caused by the vaccines) and simulated positive control outcomes. Results: Most methods show large type 1 error, often identifying false positive signals. The cohort method appears either positively or negatively biased, depending on the choice of comparator index date. Empirical calibration using effect-size estimates for negative control outcomes can bring type 1 error closer to nominal, often at the cost of increasing type 2 error. After calibration, the self-controlled case series (SCCS) design most rapidly detects small true effect sizes, while the historical comparator performs well for strong effects. Conclusion: When applying any method for vaccine safety surveillance we recommend considering the potential for systematic error, especially due to confounding, which for many designs appears to be substantial. Adjusting for age and sex alone is likely not sufficient to address differences between vaccinated and unvaccinated, and for the cohort method the choice of index date is important for the comparability of the groups. Analysis of negative control outcomes allows both quantification of the systematic error and, if desired, subsequent empirical calibration to restore type 1 error to its nominal value. In order to detect weaker signals, one may have to accept a higher type 1 error.
format Online
Article
Text
id pubmed-9299244
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92992442022-07-21 Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological Designs Schuemie, Martijn J. Arshad, Faaizah Pratt, Nicole Nyberg, Fredrik Alshammari, Thamir M Hripcsak, George Ryan, Patrick Prieto-Alhambra, Daniel Lai, Lana Y. H. Li, Xintong Fortin, Stephen Minty, Evan Suchard, Marc A. Front Pharmacol Pharmacology Background: Routinely collected healthcare data such as administrative claims and electronic health records (EHR) can complement clinical trials and spontaneous reports to detect previously unknown risks of vaccines, but uncertainty remains about the behavior of alternative epidemiologic designs to detect and declare a true risk early. Methods: Using three claims and one EHR database, we evaluate several variants of the case-control, comparative cohort, historical comparator, and self-controlled designs against historical vaccinations using real negative control outcomes (outcomes with no evidence to suggest that they could be caused by the vaccines) and simulated positive control outcomes. Results: Most methods show large type 1 error, often identifying false positive signals. The cohort method appears either positively or negatively biased, depending on the choice of comparator index date. Empirical calibration using effect-size estimates for negative control outcomes can bring type 1 error closer to nominal, often at the cost of increasing type 2 error. After calibration, the self-controlled case series (SCCS) design most rapidly detects small true effect sizes, while the historical comparator performs well for strong effects. Conclusion: When applying any method for vaccine safety surveillance we recommend considering the potential for systematic error, especially due to confounding, which for many designs appears to be substantial. Adjusting for age and sex alone is likely not sufficient to address differences between vaccinated and unvaccinated, and for the cohort method the choice of index date is important for the comparability of the groups. Analysis of negative control outcomes allows both quantification of the systematic error and, if desired, subsequent empirical calibration to restore type 1 error to its nominal value. In order to detect weaker signals, one may have to accept a higher type 1 error. Frontiers Media S.A. 2022-07-06 /pmc/articles/PMC9299244/ /pubmed/35873596 http://dx.doi.org/10.3389/fphar.2022.893484 Text en Copyright © 2022 Schuemie, Arshad, Pratt, Nyberg, Alshammari, Hripcsak, Ryan, Prieto-Alhambra, Lai, Li, Fortin, Minty and Suchard. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Schuemie, Martijn J.
Arshad, Faaizah
Pratt, Nicole
Nyberg, Fredrik
Alshammari, Thamir M
Hripcsak, George
Ryan, Patrick
Prieto-Alhambra, Daniel
Lai, Lana Y. H.
Li, Xintong
Fortin, Stephen
Minty, Evan
Suchard, Marc A.
Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological Designs
title Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological Designs
title_full Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological Designs
title_fullStr Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological Designs
title_full_unstemmed Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological Designs
title_short Vaccine Safety Surveillance Using Routinely Collected Healthcare Data—An Empirical Evaluation of Epidemiological Designs
title_sort vaccine safety surveillance using routinely collected healthcare data—an empirical evaluation of epidemiological designs
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299244/
https://www.ncbi.nlm.nih.gov/pubmed/35873596
http://dx.doi.org/10.3389/fphar.2022.893484
work_keys_str_mv AT schuemiemartijnj vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns
AT arshadfaaizah vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns
AT prattnicole vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns
AT nybergfredrik vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns
AT alshammarithamirm vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns
AT hripcsakgeorge vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns
AT ryanpatrick vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns
AT prietoalhambradaniel vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns
AT lailanayh vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns
AT lixintong vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns
AT fortinstephen vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns
AT mintyevan vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns
AT suchardmarca vaccinesafetysurveillanceusingroutinelycollectedhealthcaredataanempiricalevaluationofepidemiologicaldesigns